• Citer

Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance.

par Liefferinckx, Claire ;Minsart, Charlotte ;Cremer, Anneline ;Amininejad, Leila ;Tafciu, Vjola ;Quertinmont, Eric ;Tops, Sophie;Devière, Jacques ;Gils, Ann;Van Gossum, André ;Franchimont, Denis
Référence European journal of gastroenterology & hepatology, 31, 4, page (478-485)
Publication Publié, 2019-02-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Vedolizumab (VDZ) is effective as an induction and maintenance treatment for Crohn's disease and ulcerative colitis, but, as observed with antitumour necrosis factor-α (anti-TNFα) agents, some patients are nonetheless experiencing loss of response.